HEADER
Dr. Oz’s recent and biting criticism of laboratory pricing and CMS’s unusual fraud documentary reveal an increasingly aggressive agency.
This review examines the alleged schemes, enforcement strategy, and implications for CRUSH and exclusion authority—with one welcome observation for laboratories: the October 21 documentary and press conference did not single them out.
###
Something Old
Recall that in late August, RFK Jr recorded a 3 minute video tearing apart AMA (both AMA CPT and AMA RUC), and urging the public to comment to CMS (in an RFI) that they're mad as hell and not going to take it any longer. Here, here.
Something New
If you're around the lab industry (or the fraud industry), here are two Dr. Oz videos you need to track. One is only on Linked Iin and Facebook, the other is on Youtube [ cms.hhs.gov].
Dr. Oz Slams Lab Industry
Dr. Oz used the occasion of the PAMA data release (9/21/26) to slam the whole clinical laboratory industry for overcharging CMS billions of dollars, meaning, the delta between this year's CLFS fee schedule and the new one established by a new PAMA survey, effective January 2027.
Linked In Video. or Facebook video.
The transcript opens: “You been getting ripped off? Let me explain.”
Dr Oz then argues that:
- Medicare has paid excessive lab rates for years, with its rate-update process used only once since Congress established it in 2014.
- Medicare pays approximately 16% more than private insurers for the same tests.
- Updated rates expected in 2027, with reductions capped at 15% annually per test, would eventually eliminate more than $1 billion in annual waste.
- Publishing the data could also help Medicaid and ACA plans reduce their payments.
 |
| "Medicare paying 16% than insurers for the exact same thing" |
Dr. Oz - Mini Documentary on Fraud Strategies
There was a 30 minute fraud press conference on October 14, 2026 here.
There was also a 45 minute fraud press conference on October 21, 2026 here.
They released a detailed, 30 minute "Fraud Mini Doc" on October 21, 2026 here.
##
These three presentations describe a CMS campaign to make fraud prevention central to health program administration.
The documentary is its most revealing expression: an unusually personal, dramatic account featuring Dr. Oz, field confrontations, organized crime allegations, vulnerable patients, and Kim Brandt’s operational explanations. Its central argument is that government must stop money leaving, rather than pursue it afterward. October 14 (press conf) emphasizes duplicate insurance subsidies; October 21 (press conf + docu) demonstrates more aggressive provider and state oversight. Together, they suggest that CRUSH and CMS’s newly delegated exclusion authority belong to a broader effort to change enrollment, payment, enforcement, and public expectations about federal stewardship.
The two press conferences, briefly. October 14 is an RFK-led announcement, with substantial participation by Oz and program officials, about eliminating improper insurance subsidies and duplicate coverage. Its useful qualification comes from Oz: “This is not today overt fraud. This is sloppiness”—distinguishing the principal announcement from a separate phantom-enrollment investigation.
October 21 is more operational and confrontational. Kennedy is absent; Oz leads, supported by Inspector General March Bell, Kim Brandt, and Medicaid Director Dan Brillman.
The subjects are New York adult daycare, California personal-care spending, exclusions, audits, and state accountability. Both events frame enforcement as protecting the safety net; October 21 demonstrates how aggressively CMS intends to intervene.
Why the documentary is remarkable.
The approximately 28-minute film combines an enforcement documentary, an Oz leadership portrait, and an argument for institutional change. Its opening question—“Why does evil happen?”—immediately establishes a moral register far removed from an ordinary CMS explanation of improper-payment controls.
Oz supplies the personal narrative and confrontational presence; Brandt supplies much of the operational explanation. Recruitment stories, field encounters, arrest sequences, music, luxury purchases, and accounts of patient harm make fraud tangible. The repeated theme is “stolen trust”: fraud threatens not only budgets but public willingness to support collective programs.
My reading is that the film also seeks public support for disruptive enforcement. Near the end, Oz explicitly asks viewers to support “difficult decisions.” That matters when the decisions involve freezing payments to states, restricting enrollment, or questioning entire programs.
The following account describes the film’s allegations and explanations; the transcript itself does not independently establish every case or numerical claim.
The principal schemes and vulnerabilities include:
Easy entry into Medicare billing—the “golden ticket” problem.
Brandt recounts enrolling her dog, Sherlock, as a DME supplier using her address and bank account. The anecdote’s intended lesson is that inadequate entry screening can grant billing access before the government establishes who is really operating the business. It is an assertion in the film, not a documented enrollment audit presented to viewers. (Approximately 9:21–10:33.)DME “bust-outs” using stolen beneficiary identities.
Operators obtain Medicare numbers, bill for expensive equipment never delivered, collect payments, and move the money before beneficiaries recognize the claims. Nominal owners obscure the actual controllers, while overseas financial transfers frustrate recovery. The film identifies the delay between payment and beneficiary detection as a central vulnerability. (14:57–16:14.)Adult daycare as an entry point for multiple billing schemes.
Seniors are recruited into centers, and their identities support claims across associated medical, pharmacy, and equipment businesses. Closing one storefront leaves the controlling network intact. October 21 adds specificity: alleged cash inducements approaching $1,000, attendance sheets completed for future days, and social daycare billed as medical adult healthcare. (Documentary, approximately 14:05–14:57; press conference, 17:15–28:25.)Hospice claims involving nonexistent or ineligible patients.
The film describes “ghost patients” and people falsely represented as terminally ill. Low mortality and unusual geographic concentrations become investigative signals. A separate Carson sequence describes allegedly trafficked seniors, deceptive hospice enrollment, poor living conditions, and deficient care. The argument is that fraudulent billing can directly endanger patients. (16:14–18:51.)Operators moving between businesses and benefit categories.
Fraudsters allegedly migrate from DME to hospice or home health, or reopen through replacement entities. Brandt uses this to justify enrollment moratoria and action against the people behind businesses. The problem is recurring access to public payment, beyond any single false claim. (20:08–21:12.)Skin substitutes and payment incentives that attract abuse.
Oz describes extraordinary spending growth, very expensive products, and lavish purchases financed by billing. He presents payment reductions as a way to remove the financial attraction. This is the film’s most consequential policy example: changing reimbursement becomes an anti-fraud intervention, alongside investigations and exclusions. The film attributes the spending reversal to pricing; October 21 also credits warning letters to unusually large billers, so the presentations do not establish that pricing alone produced the result. (21:34–22:50; October 21, approximately 38:41–39:04.)
The proposed operating model follows directly: stronger screening, claims analysis before payment, faster investigations, cross-agency coordination, and sanctions that prevent reentry. Brandt’s stated ambition is to identify and remove bad actors within their first three to six months, rather than after years of billing.
What the three events reveal together.
The most important development is CMS presenting itself as an active enforcement institution, with responsibility extending from enrollment through payment and exclusion. October 21 makes this concrete: nearly 100 monitoring letters, ten notices of intent to exclude, a reported first CMS exclusion letter, California funding deferrals, and a compliance warning to New York.
The campaign also reaches beyond individual providers to intermediaries and program design. Managed-care plans are criticized for inadequate oversight; states face demands to substantiate spending; payment arrangements themselves become targets. Oz’s question about whether Medicaid should fund seniors playing mahjong crosses from detecting false claims into debating what the program should purchase. The discussion of caregiver unionization similarly extends beyond conventional billing enforcement.
The analytical caution is that these materials place several different things under the fraud banner: criminal schemes, documentation failures, duplicate enrollment, unusually high spending, and disputed policy choices. Those distinctions still matter. A statistical outlier warrants investigation; it does not establish fraud. A funding deferral is not a final finding that the entire amount was stolen. And the film’s broad allegations about prior administrations are political assertions, not demonstrated historical findings within these transcripts.
What this suggests for CRUSH.
As of October 24, the official OMB record still lists CRUSH—CMS-6098, RIN 0938-AV97—as a proposed rule under review, received August 7, 2026. The regulatory agenda projects an October proposal, but lists no legal deadline. These presentations therefore signal direction and urgency; they do not disclose the unpublished rule’s actual provisions. reginfo.gov
My expectation is that the campaign will strengthen the administration’s commitment to provisions that make intervention earlier and harder to evade:
| Documentary theme | Direction to watch in CRUSH |
|---|---|
| Billing access is too easy | Stronger identity, ownership, and enrollment verification |
| Money disappears before recovery | Faster prepayment review and payment-suspension processes |
| Operators reopen or change programs | Better coordination of revocation, preclusion, and ownership information |
| States and plans miss suspicious activity | Stronger data, oversight, and accountability requirements |
These expectations align with subjects already raised in the February CRUSH RFI. They are forecasts, not confirmed provisions. The RFI also explicitly addresses laboratory fraud, genetic and molecular testing, and the potential safeguards associated with MolDX registration. Laboratories are therefore within the regulatory discussion even though they are not a major documentary subject; these materials do not establish that nationwide MolDX requirements will appear in the proposal. federalregister.gov
Because CRUSH was already at OMB before these October events, I would interpret the film primarily as public justification and preparation for implementation, rather than evidence that the documentary generated the rule.
CMS exclusion authority is already part of the response.
The correct term is permissive exclusion. The October 14 delegation gives CMS the Secretary’s authority under Social Security Act §1128(b), while preserving OIG’s authority. It explicitly excludes authority to conduct hearings or issue regulations. Thus, CMS can make exclusion determinations under the delegation, but “conduct and finalize” should not imply control over the entire adjudicatory process or freedom from review. federalregister.gov
Three distinctions are especially relevant:
- No criminal conviction is required for important grounds, including specified excessive charges, unnecessary or substandard services, and administratively established prohibited conduct.
- “Overbilling” is shorthand, not the statutory test. Section 1128(b)(6)(A) concerns charges substantially above the provider’s usual charges, subject to qualifications; subsection (B) concerns services substantially exceeding patient needs or failing professional standards. High revenue or high utilization alone does not establish those grounds.
- Notice, hearing, and judicial-review protections remain. For §1128(b)(7), the statute generally provides a hearing before exclusion takes effect, subject to a health-or-safety exception. ssa.gov
Most tellingly, Brandt reports at approximately 20:15–21:21 on October 21 that CMS has already used the new delegation. The transcript mentions both notices of intent and a first exclusion letter, so it should not be read as proof that all ten exclusions were already effective or finally adjudicated.
The practical implication is substantial: the agency that sees suspicious payment patterns can now pursue a broader exclusion remedy itself, alongside OIG. My expectation is a shorter path from analytical flag to investigation and, where the statutory grounds are established, exclusion. CRUSH could reinforce that path through stronger enrollment and payment controls. The key question for legitimate providers will be how reliably CMS distinguishes suspicious patterns from substantiated misconduct before imposing consequences that reach across federal healthcare programs.
#
#
A Lab Industry View
Dr. Oz’s separate September 21 PAMA video opens with “You been getting ripped off? Let me explain.” He argues that Medicare pays approximately 16% more than private insurers for laboratory tests and that updated rates could eventually save more than $1 billion annually. To people working hard to deliver reliable laboratory services, that broad attack may feel unfair—or like political grandstanding over payments established by Medicare itself.
The good news: neither the October 21 fraud documentary nor its accompanying press conference specifically called out the laboratory industry. Their attention went primarily to durable medical equipment, hospice, adult daycare, personal care, and skin substitutes. Laboratories were not singled out in these prominent presentations of CMS’s enforcement campaign.
The focused takeaway is reassuring, within limits: Oz’s PAMA rhetoric was tough on laboratories, but that attack did not carry over into the October 21 fraud presentations. That does not remove laboratories from potential scrutiny under CRUSH, but their absence from this particular spotlight is welcome news.
